Omega-3 fatty acids have among the most complex and contested clinical trial records of any supplement category — a situation produced by a major divergence between two large, well-designed cardiovascular outcome trials: REDUCE-IT (2018) showed a dramatic 25% relative risk reduction in major adverse cardiovascular events with 4g/day of pure EPA (icosapentaenoic acid), while STRENGTH (2020) showed no cardiovascular benefit with 4g/day of a mixed EPA+DHA formulation. Understanding why these results diverged is essential for evaluating omega-3 cardiovascular evidence.
The current clinical consensus: pure high-dose EPA (prescription Vascepa / icosapentaenoic acid ethyl ester) has strong Phase III trial evidence for cardiovascular risk reduction in hypertriglyceridemic patients already on statins. Standard mixed EPA+DHA fish oil supplements at typical over-the-counter doses (1-2g/day combined EPA+DHA) have modest effects on triglycerides and inflammatory markers but do not have the same MACE (major adverse cardiovascular event) outcome data. For brain health and depression, DHA is the key fatty acid — 40% of brain polyunsaturated fatty acids are DHA — but EPA-dominant formulations show the strongest antidepressant signal in meta-analyses.
| Parameter | EPA (Eicosapentaenoic Acid) | DHA (Docosahexaenoic Acid) |
|---|---|---|
| Cardiovascular | Strongest evidence (REDUCE-IT); reduces triglycerides, VLDL; anti-inflammatory; platelet anti-aggregation; plaque stabilization | Reduces triglycerides similarly; but STRENGTH showed no MACE benefit as mixed EPA+DHA; modestly raises LDL-C |
| Brain / cognition | Anti-neuroinflammatory; EPA-dominant formulations are most effective for depression (Lin 2017); penetrates blood-brain barrier to some extent | Structural component of neuronal membranes (40% of brain PUFA); essential for brain development; important for cognitive maintenance |
| Depression evidence | Dominant fatty acid for antidepressant effect; ≥60% EPA ratios most effective in meta-analyses | Minimal antidepressant effect alone; DHA-dominant formulations ineffective for depression in meta-analyses |
| Pregnancy | Important but DHA is primary recommendation | Critical for fetal brain and retinal development; WHO recommends 200mg/day minimum during pregnancy; algae oil for vegetarians |
| Best form for goal | Pure EPA (Vascepa) for cardiovascular risk reduction in high-risk patients; high-EPA fish oil for mood support | Algae oil (vegan DHA); high-DHA fish oil for brain support, pregnancy, general supplementation |
Dose by goal: General cardiovascular and anti-inflammatory: 1–2g combined EPA+DHA/day; depression augmentation: 1–2g EPA specifically (look for ≥60% EPA of total omega-3 content on label); triglyceride reduction: 2–4g combined EPA+DHA/day (prescription-grade achieves this with purity; OTC requires larger capsule quantities); pregnancy: 200–300mg DHA/day minimum (most prenatal vitamins include this); high-cardiovascular-risk patients on statins with hypertriglyceridemia: prescription icosapentaenoic acid (Vascepa) 4g/day — discuss with cardiologist.
Oxidation is the biggest quality problem in fish oil: Omega-3 fatty acids are highly prone to oxidation (rancidity); oxidized fish oil may be harmful rather than helpful — produces peroxides and aldehydes; signs of rancidity: fishy smell (beyond mild), fishy burps, "off" taste; the Totox value (measure of oxidation) should be <26 mEq/kg (primary oxidation TOTOX = 2×PV + AV); only a handful of brands consistently test within acceptable limits; independent testing: IFOS (International Fish Oil Standards Program) is the most credible third-party certification; choose products with IFOS 5-star rating or equivalent third-party testing.
Form matters less than quality: Triglyceride (TG) form vs ethyl ester (EE) form: TG form has slightly better bioavailability in fasted state; EE form has equivalent or better absorption when taken with a high-fat meal; most prescription omega-3 products are EE form; re-esterified TG form (rTG) has best bioavailability overall but premium priced; algae oil: vegan DHA source; produced by the same marine algae that fish eat (so fish are just middlemen); equivalent bioavailability to fish oil DHA; preferred for vegans, vegetarians, or those concerned about ocean contaminants or sustainability.
Atrial fibrillation signal: High-dose omega-3 (≥1g/day EPA+DHA) is associated with modestly increased atrial fibrillation risk in some meta-analyses; most pronounced at doses ≥4g/day; clinically relevant in patients with existing AF history or risk factors; discuss with cardiologist if applicable; does not outweigh cardiovascular benefit in high-risk patients on the REDUCE-IT indication, but relevant to monitor.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.